A pragmatic analysis of mepolizumab in patients with aspirin-exacerbated respiratory disease

Rationale Aspirin-exacerbated respiratory disease (AERD) is a clinical syndrome defined by chronic eosinophilic rhinosinusitis, nasal polyposis, asthma, and upper and lower respiratory reactions after exposure to cyclooxygenase-1 inhibitors. Conclusions In fourteen patients with AERD, IL-5 inhibitio...

Full description

Saved in:
Bibliographic Details
Published in:Journal of allergy and clinical immunology 2018-02, Vol.141 (2), p.AB168-AB168
Main Authors: Tuttle, Katherine L., Buchheit, Kathleen M., Schneider, Thomas, Hsu Blatman, Karen S., Barrett, Nora A., Laidlaw, Tanya M., Cahill, Katherine N.
Format: Article
Language:English
Subjects:
Aspirin
Asthma
Monoclonal antibodies
Nose
Patients
Respiratory diseases
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Rationale Aspirin-exacerbated respiratory disease (AERD) is a clinical syndrome defined by chronic eosinophilic rhinosinusitis, nasal polyposis, asthma, and upper and lower respiratory reactions after exposure to cyclooxygenase-1 inhibitors. Conclusions In fourteen patients with AERD, IL-5 inhibition with mepolizumab for at least 3 months significantly improved both upper and lower airway symptom scores and notably anosmia and nasal congestion, important quality-of-life measures for AERD patients.
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2017.12.537